The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

NCT07218445 on ClinicalTrials.gov · last registry update 2026-10-06

Recruiting now, toward 40 participants. Due to report 18 September 2027, alongside 40 other tracked readouts that quarter. Primary outcome, as filed: Change in Vasomotor Symptoms Frequency. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P4
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Mayo Clinic
Sponsor type: Other
Enrollment: 40
Started: 2026-04-08
Primary completion: 2027-09-18 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Vasomotor Symptoms Frequency

Conditions studied

Obesity · Menopause Hot Flashes

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.